SCHEMBL7356339

SCHEMBL7356339

O=C(O)CN1CCN(c2ncccn2)CC1

nearest known ligand 0.66

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.66
KDM4E B2RXH2 7/20 0.66
TDP1 Q9NUW8 3/20 0.66
MDM2 Q00987 2/20 0.62
SMN1; SMN2 Q16637 2/20 0.61
TSHR P16473 1/20 0.60
HTT P42858 1/20 0.60
NPSR1 Q6W5P4 1/20 0.57
HTR1A P08908 1/20 0.57
PKM P14618 1/20 0.55
TP53 P04637 1/20 0.54
CYP2C19 P33261 1/20 0.53
DRD2 P14416 1/20 0.52
DRD4 P21917 1/20 0.52
DRD3 P35462 1/20 0.52
MAPK1 P28482 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1371732 0.98 ALDH1A1 (0.64) ALDH1A1KDM4ETDP1MDM2SMN1; SMN2
SCHEMBL4406529 0.84 ALDH1A1 (0.60) ALDH1A1KDM4ETDP1MDM2SMN1; SMN2
SCHEMBL5538980 0.84 KDM4E (0.61) ALDH1A1KDM4ETDP1MDM2SMN1; SMN2
SCHEMBL2113038 0.83 HTR1A (0.71) ALDH1A1KDM4ETDP1MDM2SMN1; SMN2
SCHEMBL28080223 0.82 ALDH1A1 (0.54) ALDH1A1KDM4ETDP1MDM2SMN1; SMN2
SCHEMBL18088545 0.81 ALDH1A1 (0.47) ALDH1A1KDM4ETDP1MDM2SMN1; SMN2
SCHEMBL21780812 0.81 ALDH1A1 (0.49) ALDH1A1KDM4ETDP1MDM2SMN1; SMN2
SCHEMBL5174282 0.80 NPSR1 (0.71) ALDH1A1KDM4ETSHRHTTNPSR1
SCHEMBL9533727 0.80 HTR1A (0.64) ALDH1A1KDM4ETDP1NPSR1HTR1A
Hydrochloric Acid SCHEMBL9532906 0.79 HTR1A (0.62) ALDH1A1KDM4ETDP1NPSR1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118307525-A Iridoid compound, preparation method thereof, pharmaceutical composition and application thereof 安徽中医药大学 2024-07-09 CN claimed
CN-118307525-A Iridoid compound, preparation method thereof, pharmaceutical composition and application thereof 安徽中医药大学 2024-07-09 CN disclosed
US-20230374034-A1 NOVEL BICYCLIC COMPOUNDS Prism BioLab Co., Ltd. (JP) 2023-11-23 US disclosed
US-20230374034-A1 NOVEL BICYCLIC COMPOUNDS Prism BioLab Co., Ltd. (JP) 2023-11-23 US disclosed
WO-2022075486-A1 NOVEL BICYCLIC COMPOUNDS Prism BioLab Co., Ltd. (JP) 2022-04-14 WO disclosed
WO-1999048911-A1 MONOBACTAM ENZYME INHIBITORS NAEJA PHARMACEUTICAL INC. (GB) 1999-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230374034-A1 NOVEL BICYCLIC COMPOUNDS NOTCH1, NOTCH2, HES1 ALDH1A1 1622/4885KDM4E 1654/4885TDP1 4179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.